

Yearly update of advances in medical oncology

2017

20-21 Απριλίου 2018
Divani Palace Acropolis Hotel
Αθήνα



Υπό την Αιγίδα των:



Οργάνωση



Θα χορηγηθούν μόρια Συνεχιζόμενης Ιατρικής Εκπαίδευσης (CME > CPD credits)
ΔΗΛΩΣΕΙΣ ΣΥΜΜΕΤΟΧΗΣ στο info@scper.gr

Χαιρετισμός

Αγαπητοί συνάδελφοι και φίλοι,

Με ιδιαίτερη χαρά σας προσκαλούμε στη Διημερίδα με τίτλο «Yearly update of Advances in Medical Oncology 2016» που διοργανώνεται από το Ελληνικό Forum Ογκολογίας.

Το σύνολο της ετήσιας δημοσιεύμενης βιβλιογραφίας που αφορά την ογκολογία είναι τεράστια, καθιστώντας εκ των πραγμάτων προβληματική την καθημερινή και σε βάθος παρακολούθηση της. Λαμβάνοντας υπόψη τη θετική ανταπόκριση που είχε το ανάλογο εγκέριμα πέρυσι, αποφασίσθηκε για δεύτερη συνεχή χρονία να παρουσιασθούν οι πιο σημαντικές ογκολογικές μελέτες που έχουν δημοσιευθεί ως πλήρη άρθρα σε περιοδικά με υψηλό impact factor μέσα στο 2017, σε ένα εντατικό διήμερο.

Μία ομάδα έμπειρων συναδέλφων επέλεξε άρθρα, τα οποία δίνουν ουσιαστικές προοπτικές αλλαγής της καθημερινής ογκολογικής πρακτικής.

Ο στόχος είναι, μέσω της αναλυτικής παρουσίασης των μελετών και το σχολιασμό τους, να βελτιωθεί η κλινική γνώση και η ποιότητα της καθημερινής πρακτικής.

Ευχαριστούμε πολύ για τη συμμετοχή σας.

Εκ μέρους της Οργανωτικής Επιτροπής

Παναγιώτης Κατσαούνης



MD, MSc, Παθολόγος - Ογκολόγος
Επιμελήτης Α' Ογκολογικό Τμήμα,
«ΙΑΣΩ General», Αθήνα
Πρόεδρος Επιστημονικής Επιτροπής

Βασίλειος Γεωργούλιας



Ομότιμος Καθηγητής Παθολογίας Ογκολογίας
Ιατρική Σχολή Πανεπιστημίου Κρήτης
Πρόεδρος Οργανωτικής Επιτροπής

Οργανωτική Επιτροπή

B. Γεωργούλιας

Π. Κατσαούνης

Επιστημονική Επιτροπή

Πρόεδρος

Π. Κατσαούνης

Μέλη

- A. Αργύρης
- X. Εμμανουηλίδης
- Z. Ζαφειρίου
- N. Κεντεποζίδης
- A. Κουμαριανού
- P. Κουντουράκης
- A. Κούτρα
- A. Κουσάπουλος
- E. Λιανίδης
- E. Ραζή
- E. Τιμοθεάδης
- M. Τόλια



CYRAMZA® (ramucirumab)

TAKE ACTION



**TRAINED TO MAKE
A DIFFERENCE
ABLE TO MAKE
AN IMPACT**

Βοηθάτε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΑΕΣ τις συντεθύμυτες ενέργειες για GIA τα φάρμακα
Συμπληρωματικά, την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Για περιοδικές πληροφορίες απευθυνθείτε στην Εταιρεία:

CYRAMZA/ADV/00100-2018 CONVEY



ΦΑΡΜΑΣΕΠΒ - ΛΙΛΥ Α.Ε.Β.Ε.

15ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας, 14564 Κηφισιά ΤΗλ.: 210 6294600 Fax: 210 6294610
Για παραγγελίες: ΤΗλ.: 210 6294629 Fax: 210 6294630 e-mail: orders@lilly.gr www.lilly.gr



Yearly update of advances in medical oncology 2017

Friday, April 20th, 2018

08.00-09.00 Registration

09.00-09.45 **Session 1: General Issues**

Moderators: Ch. Emmanouilides, S. Xynogalos

09.00-09.15 ▶ Mediterranean diet and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition cohort

▶ ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia

▶ Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil–lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma

09.15-09.30 ▶ Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial

▶ Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?

▶ Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study

09.30-09.45 Q & A and Comments

09.45-10.30 **SESSION 2: CIRCULATING BIOMARKERS (CTCs and ctDNA)**

Moderators: A. Markou, V. Georgoulias

09.45- 10.00 ▶ Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study

▶ Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

▶ ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment

10.00-10.15 ▶ Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma

▶ Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease

▶ Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients

10.15-10.30 Q & A and Comments

10.30-11.00 Coffee break

E. Ntouvelis

K. Rapti

E. Tzanikou

A. Markou



TAGRISSO

(osimertinib)

Όνομασία του φαρμακευτικού προϊόντος:

TAGRISSO 40 mg επικαλυμμένα με ήπειρό υμένιο δισκία
TAGRISSO 80 mg επικαλυμμένα με ήπειρό υμένιο δισκία

Ποιοτική και ποσοτική σύνθεση:

TAGRISSO 40 mg Δισκία. Κάθε δισκίο περιέχει 40 mg οσιμερτίνινης (ως μεσοπήκτης).
TAGRISSO 80 mg Δισκία. Κάθε δισκίο περιέχει 80 mg οσιμερτίνινης (ως μεσοπήκτης).

Για περισσότερες συνταγογραφικές πληροφορίες απευθυνθείτε στην εταιρεία AstraZeneca A.E.

▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επηρέψει ταν γρήγορα προσβορισμό των πληροφοριών ασφαλίσεως. Σητείται από τους επαγγελματίες υγείας να αναθέρνουν οποιαδήποτε πιθανογόνουσες ανεπιθύμητες ενέργειες στον Εθνικό Οργανισμό Φορητών, Μεσογείων 284 GR-15562 Χαλαρών, Αθήνα, Τηλ: + 30 21 32040380/337, Φοξ: + 30 21 06549565, Ιστόσελος: <http://www.eof.gr>



Θεοτοκοπούλου 4 & Αστροναυτών, 151 25 Μαρούσι, Αθήνα
Τηλ.: 210 6871500, Fax: 210 6859195
Τηλ. ποραγγελιών: 216 2000000, Fax: 210 5596973
www.astrazeneca.gr

Yearly update of advances in medical oncology 2017

11.00-12.00 Session 3: Head and Neck Cancers

Moderators: A. Argiris, M. Balafouta

- 11.00-11.15 ▶ Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer M. Bakogeorgos

▶ Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

▶ Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

- 11.15-11.30 ▶ Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma M. Rovithi

▶ Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial

▶ Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

- 11.30-11.45 ▶ What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis C. Avgerinou

▶ Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study

▶ Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial

11.45-12.00 Q & A and Comments

12.00-13.00 Session 4: Colorectal tumors

Moderators: A. Koumarianou, P. Kountourakis

- 12.00-12.15 ▶ Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study A. Vagianos

▶ Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2

▶ Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

- 12.15-12.30 ▶ TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

▶ Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial

▶ Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials



Πρώτη πανευρωπαική συμμετοχή
των Επίλογων Ασθενούς και Βρεφών
διαδικασία για την επέμβαση σε ασπεσία
και λεπτότητα
ΕΜΑ της αναστολής επέμβασης για
ΟΑΑ σε γλυκόζη
Συγκριτικά με τη «ΕΛΤΙΠΕΡΑ ΚΑΡΤΑ»

Yearly update of advances in medical oncology 2017


- 12.30-12.45 ▶ Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et RechercheenCancerologie Digestive Database **G. Lambrodimou**
- ▶ Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
- ▶ Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
- 12.45-13.00 Q & A and Comments
- 13.00-14.30 **Lunch**
- 14.30-15.45 **Session 5: CNS, Genetics**
Moderators: **E. Razi, A. Koutsopoulos**
- 14.30-14.50 ▶ Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma **G. Rigakos**
- ▶ Lomustine and Bevacizumab in Progressive Glioblastoma
- ▶ Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- 14.50-15.10 ▶ Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer **P. Kourlouris**
- ▶ Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers
- ▶ Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma
- 15.10-15.30 ▶ MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
- ▶ Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung
- ▶ Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
- 15.30-15.45 Q & A and Comments
- 15.45-17.00 **Session 6: Breast Cancer**
Moderators: **A. Koutras, D. Tryfonopoulos**
- 15.45-16.05 ▶ Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy **M. Theochari**
- ▶ Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- ▶ Utidolone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
- 16.05-16.25 ▶ Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation **S. Karageorgopoulou**
- ▶ Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients
- ▶ MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy



AVASTIN®



Roche



 Roche
med

Roche (Hellas) A.E.
Αλαμάνος 4 & Διεύθυνση 151 25 Μαρούσι, Αττική
τηλ: 210 61 66100, fax: 210 61 66159
email: hellas.medinfo@roche.com
τηλ: 800 111 93 00 Ελλάδα (Επαρχιακό γραφείο επικοινωνίας)
τηλ: 800 92 668 Κύπρος, (Επαρχιακό γραφείο επικοινωνίας)

Βοηθήστε να γίνουν τα φάρμακα πιο οσιαλή και
Αναφέρετε
ΟΛΣ ΤΙΣ ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώστε την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



Επικοινωνίας την ιστοσελίδα του AVASTIN
στο www.rochemed.gr

Avastin 25mg/ml πικνό διάλυμα για παρασκευή διαλύματος προς έγκωμα
Πιερατήρια πληρωμορίες δικαιθείσται από την εταιρεία
Roche Hellas A.E., κατόπιν απήσεως
τηλ: 800 92 668 Κύπρος, (Επαρχιακό γραφείο επικοινωνίας)



AVASTIN®
bevacizumab

Η εταιρία Roche Hellas A.E. είναι μετοχοποιημένη με ISO 9001:2008

16.25-16.45 ▶ Oral Bisphosphonates and Improved Survival of Breast Cancer

E. Moirogiorgou

▶ Trastuzumabemtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

▶ Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)

16.45-17.00 Q & A and Comments

17.00-17.30 Coffee break

17.30-18.45 Session 7: Sarcoma-Melanoma

Moderators: E. Lagoudaki, Ch. Kosmas

17.30-17.50 ▶ Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

A. Laskarakis

▶ Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

▶ Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

17.50-18.10 ▶ Burden and centralised treatment in Europe of rare tumours:
results of RARECAREnet—a population-based study

N. Diamantopoulos

▶ Gemcitabine and docetaxel versus doxorubicin as first-line treatment
in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDIS):
a randomised controlled phase 3 trial

▶ Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment
With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis
of Randomized Phase II and III Trials

18.10-18.30 ▶ Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune
disorders or major toxicity with ipilimumab

K. Stouraiti

▶ A phase II study of a human anti-PDGFR α monoclonal antibody (claratumab, IMC-3G3)
in previously treated patients with metastatic gastrointestinal stromal tumors

▶ Activity and safety of crizotinib in patients with advanced clear-cell sarcoma
with MET alterations: European Organization for Research and Treatment
of Cancer phase II trial 90101 'CREATE'

18.30-18.45 Q & A and Comments

18.45-20.00 Session 8: Upper GI Tumors

Moderators: N. Kentepozidis, A. Karampeazis

18.45-19.05 ▶ Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival
and final overall survival from a phase III randomized study

M. Paraskeva

▶ Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose
Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients
With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or
Gastroesophageal Junction Adenocarcinoma

► Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial

19.05-19.25 ► Whole-genome landscape of pancreatic neuroendocrine tumours

► Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

► Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

19.25-19.45 ► Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

► CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial

► Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base

19.45-20.00 Q & A and Comments

Session 9: Gynecological Cancer

Moderators: E. Timotheadou, C. Christofyllakis

20.00-20.20 ► Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

► Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

► Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum

20.20-20.40 ► Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

► Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

► Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

20.40-21.00 Q & A and Comments

E. Lagoudaki

I. Kotsantis

S. Kaltsas

E. Maragouli

SATURDAY, April 21st, 2018

09.10-10.00 Session 10: Biomarkers

Moderators: I. Pateras, A. Koutsopoulos

09.10-09.30 ► A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer

A. Tzovaras

► A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity

09.30-09.50 ► Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients

V. Ramfisidis

► Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology and the American Society of Clinical Oncology

09.50-10.00 Q & A and Comments

10.00-11.15 Session 11: Urogenital Cancer

Moderators: Z. Zafeirou, N. Alevizopoulos

10.00-10.20 ► Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

E. Lianos

► Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

► Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

10.20-10.40 ► Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

N. Pavlidis

► Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide

► A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157

10.40-11.00 ► Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

E. Bournakis

► Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

► Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial - FIRSTANA

11.00-11.15 Q & A and Comments

11.15-12.00 Coffee break

12.00-13.00 **Session 12: Immuno-Oncology and Immunotherapy**

Moderators: A. Kotsakis, K. Vetsika

- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

- Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy

- The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast

- An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer

- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy

- Q & A and Comments

13.00-14.30 **Lunch**14.30-16.20 **Session 13: Lung Cancer**

Moderators: A. Kotsakis, P. Katsaounis

- Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy

- Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer

- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer

- Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

- Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

- Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group

- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

- Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies

- Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer - A Multicenter Retrospective Study

N. Tsoukalas**E. Eleftherakis-Papaikovou****P. Katsaounis****E. Kontopidis****F. Koinis****M. Nikolaou**

- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

- Q & A and Comments

16.20-17.45 **Session 14: Radiotherapy**

Moderators: I. Georgakopoulos, M. Tolia

- Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial

- Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC-3): a multicentre, randomised, controlled, phase 3 trial

- Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001

- Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials

- Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial

- Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study

- Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database

- Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer

- Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer

- Q & A and Comments

17.45-18.45 **Closing Remarks****A. Giannopoulou****A. Stergioula****A. Gantaifi**

Ευρετήριο Ομιλητών-Προέδρων

Alevizopoulos Nektarios MD, Medical Oncologist, Evangelismos General Hospital, Athens, Greece

Argiris Athanasios MD, PhD, FACP, Consultant Medical Oncologist, Hygeia Hospital, Athens, Greece, Professor, Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA, Adjunct Professor, University of Texas Health Science Center at San Antonio, Texas, USA

Avgerinou Chrysanthi Medical Oncology Resident, Oncology Unit, 2nd Department of Internal Medicine, Attikon University Hospital, Athens, Greece

Bakogeorgos Marios Medical Oncologist, 251 Hellenic Airforce General Hospital, Athens, Greece

Balafouta Myrsini Radiotherapist Oncologist, Lecturer University of Athens, Greece

Bournakis Evangelos MD, Medical Oncologist, Scientific Associate Oncology Unit Areteio University Hospital of Athens, Iaso General Clinic of Athens, Greece

Christofyllakis Charalampos Director of the Department of Medical Oncology, 401 General Military Hospital of Athens, Greece

Diamantopoulos Nikolaos Medical Oncologist, A' Dpt of Medical Oncology, Theagenio Hospital, Thessaloniki, Greece

Eleutherakis-Papaiakovou Evangelos MD, PhD, Medical Oncologist, Locum Consultant at Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece

Emmanouilides Christos MD, PhD, Professor of Medical Oncology, Dept. of Hematology & Medical Oncology, UCLA, CA, USA & European Interbalkan Medical Center, Thessaloniki, Greece

Gantaifi Areti MD, Radiation Oncologist, Interbalkan Medical Center, Thessaloniki, Greece

Georgakopoulos Ioannis Radiation Oncologist, 401 Military Hospital, IASO Hospital, Athens, Greece

Georgoulias Vasileios Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Greece

Giannopoulou Alexandra MD, MSc, Radiation Oncologist, IASO Radiotherapy Department, Athens, Greece

Kaltsas Serafeim Medical Oncologist, Consultant 3rd Oncologic Clinic Metropolitan Hospital, Athens, Greece

Karageorgopoulou Sofia MD, Medical Oncologist, IASO Clinic, Medical Oncology Department

Karampeazis Athanasios MD, Medical Oncology Consultant, 401 Army General Hospital Hospital, Athens, Greece

Katsaounis Panagiotis MD, Medical Oncologist, 1st Oncology Unit, IASO General, Athens, Greece

Kentepozidis Nikolaos M.D, PhD, Medical Oncologist, Head of Oncology Clinic, 251 General Airforce Hospital, Athens, Greece

Koinis Phillipos Consultant Medical Oncologist, Iatrido Athinon, Scientific Associate, Member of the Molecular Carcinogenesis Group, Laboratory of Histology and Embryology Medical School, National and Kapodistrian University of Athens

Kontopodis Emmanouil MD, Medical Oncologist, Venizeleion General Hospital of Heraklion

Kosmas Christos MD, PhD, Consultant Medical Oncologist & Head Hematopoietic Cell Transplant Unit, Department of Medicine, «Metaxa» Cancer Hospital, Piraeus, Greece

Kotsakis Athanasios MD, PhD, Associate Professor of Medical Oncology, School of Medicine, University of Thessaly, General University Hospital of Larissa

Kotsantis Ioannis MD, Medical Oncologist, Oncology Unit, 2nd Department of Internal Medicine, ATTIKON University Hospital, Athens, Greece

Koulouris Andreas MD, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece

Koumarianou Anna MD, PhD in Tumor Immunotherapies, Imperial College, Consultant in Medical Oncology, Hematology-Oncology Unit, ENETs Centre of Excellence, Fourth Department of Internal Medicine, Attikon University Hospital, Athens, Greece

Kountourakis Panteleimon MD, PhD, Consultant Medical Oncologist, Medical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

Koutras Aggelos Assistant Professor in Medical Oncology, University of Patras, Greece

Koutsopoulos Anastasios MD, PhD, Assistant Professor of Pathology, Faculty of Medicine, University of Crete, Laboratory of Pathology, University Hospital of Heraklion, Heraklion, Crete, Greece

Lagoudaki Eleni MD, Consultant in Pathology, University Hospital of Heraklion, Heraklion, Crete

Lambrodimitri Georgia Medical Oncologist, "Metaxa Cancer Hospital", Piraeus, Greece

Laskarakis Apostolos MD, MSc, Medical Oncologist, Consultant at 1st Oncology Clinic, Metropolitan Hospital of Athens, Greece

Lianos Evangelos MD, Consultant of Medical Oncology, Dpt METAXA Memorial Cancer Center Hospital, Piraeus, Greece

Maragouli Eleni MD, Medical Oncologist, University of Thessaly, Biologist, Aristotle University of Thessaloniki, Greece

Markou Athina PhD, Postdoctoral Researcher, Lab of Analysis Circulating Tumor Cells (ACTC), Lab of Analytical Chemistry, Dept of Chemistry, University of Athens, Athens, Greece

Mirogiorgou Evangelia Medical Oncologist, Hygeia Hospital, Athens, Greece

Nikolaou Michail MD, MSc, PhD, Medical Oncologist, General and Maternity Hospital "Elena Venizelou", Athens, Greece

Ntouvelis Evangelos MD, PhD, Medical Oncologist, Corfu General Clinic, Corfu, Greece.

Paraskeva Maria Medical Oncologist, General Hospital of Rhodes, Rhodes, Greece

Pateras Ioannis Assistant Professor, Bsc, MD, PhD, Pathologist, Molecular Carcinogenesis Group, Laboratory of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Pavlidis Nektarios MD, MSc, Medical Oncologist, University Hospital of Lausanne, Swiss

Ramfidis Vasileios MD, MSc, Consultant Medical Oncologist, Dpt. of Medical Oncology, 251 Airforce General Hospital of Athens, Greece

Rapti Kleopatra MD, MSc, Consultant Medical Oncologist, Department of Medical Oncology, 251 Airforce General Hospital of Athens, Greece

Razis Evangelia MD, PhD, Medical Oncologist, Director 3rd Oncology Department, Hygeia Hospital, Athens, Greece

Rigakos Georgios MD MSc, Medical oncologist, 3rd oncology department, Hygeia Hospital, Athens, Greece

Rovithi Maria Medical Oncology Unit, Dpt of Internal Medicine, Agios Nikolaos G. Hospital, Crete, Greece

Stergioula Anastasia Radiation Oncologist, Department of Radiation Oncology "Iaso", Athens, Greece

Stouraiti Kalliopi Medical Oncologist, Euroclinic of Athens, Athens, Greece

Theochari Maria MD, Consultant B' of Medical Oncology, Oncology Unit, Hippokrateion University Hospital, Athens, Greece

Timotheadou Eleni MD, PhD, Assistant Professor of Medicine Oncology, Aristotle University Of Thessaloniki, Greece

Tolia Maria MD, Msc, PhD, Assistant Professor of Radiotherapy, Radiotherapy/Radiation Oncology Dept, Faculty of Medicine, School of Health Sciences, University of Thessaly - University Hospital of Larissa, Greece

Tryfonopoulos Dimitrios Consultant Medical Oncologist, St. Savas Anticancer Hospital, Athens, Greece

Tsapakidis Konstantinos Medical Oncologist, University Hospital of Larissa, Greece

Tsigaridas Konstantinos Medical Oncologist, A' Oncology Unit, Metropolitan Hospital of Athens, Greece

Tsoukalas Nikolaos MD, MSc, PhD, Medical Oncologist, MSc in Bioinformatics, Consultant at Veterans Hospital (NIMTS), Athens Greece

Tzanikou Eleni PhD candidate, Laboratory of Analytical Chemistry, Analysis of Circulating Tumor Cells (ACTC) Lab, Dept of Chemistry, University of Athens, Athens, Greece

Tzovaras Alexandros PhD, Medical Oncologist, Henry Dynnant Hospital, Athens Medical Center, Athens, Greece

Vagianos Anastasios Medical Oncologist, University General Hospital of Thessaloniki "AHEPA", 1st Propaedeutic Internal Medicine Dpt /Oncology Day Unit, Thessaloniki, Greece

Vetsika Eleni-kyriaki MPhil, PhD, Biochemist, Research Associate, Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, Greece

Xynogalos Spyridon MD, PhD, Consultant Medical Oncologist, Metaxa Memorial Cancer Hospital, Piraeus, Greece

Zafeiriou Zafeiris MD, MSc, Medical Oncologist, Theageneion Anticancer Hospital, Thessaloniki, Greece

Γενικές πληροφορίες

Διοργάνωση



Ημερομηνία Διεξαγωγής

20-21 Απριλίου 2018

Χώρος Διεξαγωγής

Ξενοδοχείο, Divani Palace Acropolis Hotel,
Παρθενώνος 19, Αθήνα, ΤΚ:117 42
Τηλέφωνο: 210 9280100

Υπό την Αιγίδα



Εγγραφή

Η εγγραφή στη Διημερίδα είναι δωρεάν

Γλώσσα

Η επίσημη γλώσσα της διημερίδας θα είναι η Ελληνική

Πιστοποιητικό Παρακολούθησης

Το Πιστοποιητικό Παρακολούθησης θα δοθεί στους συμμετέχοντες μετά το πέρας των εργασιών της Διημερίδας. Βάσει της τελευταίας εγκυκλίου του ΕΟΦ, θα υπάρχει σύστημα καταμέτρησης του χρόνου παρακολούθησης. Η πιστοποίηση παρακολούθησης θα δίνεται σε όσους έχουν συμπληρώσει τουλάχιστον το 60% των συνολικών ωρών του προγράμματος. Ο αριθμός Μορίων της Συνεχιζόμενης Ιατρικής Εκπαίδευσης (CME-CPD) που θα χορηγηθεί στους συμμετέχοντες, θα υπολογιστεί βάσει χρόνου παρακολούθησης. Η διημερίδα μοριοδοτείται με μόρια (Credits) Συνεχιζόμενης Ιατρικής Εκπαίδευσης.

Γραμματεία Διημερίδας



Scientific | Cultural Events and Publications

T +30 2810 222155, +30 210 7240039

F +30 2810 222156, +30 210 7240139

E info@scep.gr

www.scep.gr

Συμειώσεις

Χορηγοί

Ευχαριστούμε θερμά τις παρακάτω εταιρείες για την ουσιαστική συμβολή τους, στην πραγματοποίηση του συνεδρίου



Η σειρά καταχώρησης των εταιρειών είναι κατά αλφαριθμητική σειρά



Η Astellas είναι αφοσιωμένη στο να μετατρέπει την επιστημονική καινοτομία σε ιατρικές λύσεις που αποφέρουν αξία και ελπίδα στους ασθενείς παγκοσμίως.

Δέσμευθμαστεί να καταπολέμησουμε τον καρκίνο και να διαθέσουμε καινοτόμες θεραπείες που μπορούν να παρατείνουν και να βελτιώσουν τη ζωή των ανθρώπων που πάσχουν από καρκίνο.

Για να το πετύχουμε αυτό, εστιάζουμε τις προσπάθειες μας σε τομείς όπου μπορούμε να αναπτύξουμε τα καλύτερα φάρμακα στην κατηγορία τους, και εκεί όπου υπάρχουν πραγματικές θεραπευτικές ανάγκες για τους ασθενείς.

Κατά συνέπεια ένας σημαντικός αριθμός μαρτιών είναι ήδη σε φάση κλινικής ανάπτυξης ειών πολλά περισσότερα βρίσκονται ακόμα σε πρώτα ερευνητικό στάδιο.

Στην Astellas, εστιάζουμε στο να κάνουμε πραγματικότητα το αλλάζοντας το αύριο.

astellas.gr



© September 2017 Astellas Pharmaceuticals A.E.E.E. GR/NPF/0917/0024



Scientific | Cultural Events and Publications

T +30 2810 222155, +30 210 7240039 F +30 2810 222156, +30 210 7240139 E info@scep.gr www.scep.gr